Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05710926
Other study ID # ESTS-23
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 5, 2022
Est. completion date January 1, 2025

Study information

Verified date July 2023
Source Tages Onlus
Contact Simone Cheli, PhD
Phone +393285642442
Email simone.cheli@tagesonlus.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims at replicating existing preliminary evidence about the effectiveness of Evolutionary Systems Therapy for Schizotypy (ESTS). The present randomized controlled trial (RCT) will compare ESTS with Cognitive Behavioral Therapy (CBT) in treating Schizotypal Personality Disorder (SPD). The main questions our RCT aims to answer are: 1. Is ESTS more effective than CBT in treating SPD? 2. Is ESTS more feasible than CBT in treating SPD? 38 patients diagnosed with SPD will be recruited and randomly allocated to either the experimental group (i.e. ESTS) or the control group (CBT). Primary outcome will be reduction in general symptomatology, whereas secondary outcomes will be changes in target mechanisms (self-criticism and metacognition) and remission from diagnosis.


Description:

A previous study suggested how ESTS (experimental group; EG) may be not inferior in respect to a combine treatment comprising of CBT and psychopharmacological treatment (control group; CG). Despite the encouraging results, it has been suggested that the presence in the CG of a mandatory pharmacological treatment would have represented a bias. Indeed, a few partecipants refused pharmacological treatment. Thus, the investigators outlined an RCT aimed at comparing the two interventions (ESTS and CBT) without any mandatory pharmacological treatment. Moreover, the investigators consider the need for a pharmacological treatment during the study as an exclusion criterion. The investigators expect to extend our knowledge about the feasbility and effectiveness of ESTS for those diagnosed with SPD:


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date January 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Schizotypal Personality Disorder at SCID-5-AMPD Module III - Age 18 or older - Being capable of reading and signing the inform consent form in Italian - Being capable of attending a talk therapy in Italian Exclusion Criteria: - Being diagnosed with schizophrenia spectrum disorders or other psychosis disorder - Being diagnosed with neurodevelopmental or neurological disorders - Being diagnosed with bipolar disorder - Being under any psychological or pharmacological treatment

Study Design


Intervention

Behavioral:
Evolutionary Systems Therapy for Schizotypy
A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
Cognitive Behavioral Therapy
An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.

Locations

Country Name City State
Italy Centro di Psicologia e Psicoterapia Tages Onlus - Firenze Firenze FI

Sponsors (1)

Lead Sponsor Collaborator
Tages Onlus

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in general symptomatology Change in the total score of Symptom Checklist-90-R (SCL-90-R) between two measurements 2 measurements: one at baseline assessment; one at final assessment
Secondary Change in metacognition Change in total score of Metacognition Assessment Scale - Abbreviated (MAS-A) between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Secondary Change in critical beliefs about self Change in the Hated-self scale of The Forms of Self-Criticizing/attacking and Self-reassuring Scale (FSCRS) between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Secondary Change in critical beliefs about others Change in Socially prescribed perfectionism scale of Multidimensional Perfectionism Scale (MPS) between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Secondary Change in schizotypal traits 1 Change in Psychoticism scale of Personality Inventory for DSM-5 (PID-5) between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Secondary Change in schizotypal traits 2 Change in Detachment scale of Personality Inventory for DSM-5 (PID-5) between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Secondary Change in remission from primary diagnosis Change in Diagnosis of Schizotypal Personality Disorders trough Structured Clinical Interview for the DSM-5 Alternative Model for Personality Disorders (SCID-5-AMPD) Module III between two measurements 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
See also
  Status Clinical Trial Phase
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Terminated NCT00353379 - Pharmacology of Cognition in Schizotypal Personality Disorder Phase 4
Recruiting NCT00252044 - Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder N/A
Completed NCT00158028 - Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder N/A
Completed NCT02800681 - Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
Completed NCT02524899 - CRT-Guanfacine for SPD Phase 2
Recruiting NCT01466205 - Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Phase 2
Completed NCT02535156 - Schizotypal Personality Disorder Risperidone Phase 1/Phase 2
Completed NCT04764708 - Compassion and Metacognition in Schizotypal Personality N/A
Completed NCT02507206 - A D1 Agonist For Working Memory Phase 2